Aerie Pharmaceuticals reported a net loss of $55 million, or $1.40 per share, in the second quarter of 2018, compared to a net loss of $28.4 million, or $0.82 per share, in the same period of 2017.
Total costs and expenses for the quarter totaled $58.1 million, compared to $27.8 million in 2017, while research and development costs rose from $10.6 million in 2017 to $18.2 million this year.
Selling, general and administrative costs increased from $17.2 million to $39.9 million.
The higher costs were attributed to increased activities supporting (Read more...)
Uncategorized